Table 2. Patients undergoing resections within the First BEAT and N016966 trials.
| No. of patients undergoing surgery with curative intent (%) | No. of patients undergoing R0 resection (%) | % Of curative- intent resections that were R0 | Hepatic resections with curative intent (%) | R0 hepatic resections (%) | % Of hepatic resections that were R0 | |
|---|---|---|---|---|---|---|
| First BEAT | ||||||
| All evaluable patients (ITT population) n=1914 | 225 (11.8%) | 173 (9.0) | 76.9 | 145 (7.6) | 114 (6.0) | 78.6 |
| Patients receiving oxaliplatin-based chemotherapy n=949 | 153 (16.1) | 116 (12.2) | 75.8 | 99 (10.4) | 76 (8.0) | 76.8 |
| Patients receiving irinotecan-based chemotherapy n=662 | 64 (9.7) | 49 (7.4) | 76.6 | 43 (6.5) | 34 (5.1) | 79.1 |
| NO16966 | ||||||
| XELOX or FOLFOX4 + bevacizumab n=699 | 59 (8.4) | 44 (6.3) | 74.6 | — | — | — |
| XELOX or FOLFOX4 + placebo n=701 | 43 (6.1) | 34 (4.9) | 79.1 | — | — | — |
Abbreviations: BEAT=bevacizumab expanded access trial; FOLFOX4=5-FU and oxaliplatin; ITT=intention to treat; XELOX=capecitabine plus oxaliplatin.